Large Retrospective Study Reports Greater Symptom Relief with Neurolens Contoured Prism Technology
Friday, February 20 2026 | 10 h 35 min | News
Newton™, Inc. (formerly Neurolens®) has released results from a retrospective analysis of 96,745 patient records examining outcomes of prism-based treatment for binocular vision anomalies.
According to the company, the dataset, collected from provider locations between September 2023 and October 2025, found patients wearing Neurolens lenses with Contoured Prism™ technology experienced greater symptom improvement than those using conventional prism correction.
Reported outcomes included:
- 41% greater improvement in headaches
- 53% greater improvement in neck and shoulder stiffness
- 27% greater improvement in tired-eye symptoms
- 28% greater improvement in overall symptom scores
The company describes the dataset as one of the largest real-world analyses evaluating prism treatment outcomes. Statistical analysis indicated improvements in the Neurolens group were significant compared with both conventional prism and control groups (p<0.01).
Neurolens differs from conventional prism by varying prism power from distance to near rather than applying a uniform correction across the entire lens surface. The design is intended to match changing alignment demands throughout the day.
Supporting materials from the company also reference a previously published randomized controlled clinical trial using the HIT-6 questionnaire, as well as findings suggesting reduced “prism creep,” in which prism requirements increase over time.
Based on the study results, the manufacturer indicates the technology may be considered for patients presenting with symptoms such as headaches associated with near work, neck and shoulder tension, and end-of-day visual fatigue.
The full white paper is available HERE.
Click HERE for the press release.
Want to see more like this article? Click here to subscribe to our FREE print magazines and e-newsletters!
